The authorized share increase vote is the key binary catalyst — passage would enable future equity raises or M&A currency. The activist SC 13D context suggests potential board challenge or strategic demands. Monitor for dissident proxy materials and vote outcome on December 3.
Price Chart
Executive Summary
Galectin Therapeutics filed DEFA14A definitive additional proxy soliciting materials on October 13, 2026, in connection with its upcoming annual meeting scheduled for December 3, 2026. The filing follows a recent SC 13D/A from activist Richard E. Uihlein (filed August 4, 2026), indicating an active proxy contest context. The annual meeting will include election of 11 directors, a proposal to increase authorized common shares from 150M to 250M, and an amendment to the 2019 Omnibus Equity Incentive Plan to reserve an additional 3M shares.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for December 3, 2026, virtual format
- 11 nominees for director to be elected
- Proposal to increase authorized common shares from 150,000,000 to 250,000,000
- Proposal to amend 2019 Omnibus Equity Incentive Plan to reserve additional 3,000,000 shares
- Ratification of Cherry Bekaert LLP as independent auditor for FY2026
- Record date for voting is October 6, 2026
- SC 13D/A filed by Richard E. Uihlein on August 4, 2026 indicates activist presence
Financial Impact
Authorized share increase of 100M shares (67% expansion) and 3M additional shares for equity plan represent significant potential dilution, though no specific dollar amounts disclosed
Risk Factors
- Shareholder approval of 67% authorized share increase could enable significant future dilution
- Activist campaign by Richard Uihlein may escalate into proxy fight or board representation demands
- Equity plan expansion may increase compensation-related dilution
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-039380 |
| Document: 0001140361-26-039380-index-headers.html | 0001140361-26-039380 |
| Document: 0001140361-26-039380-index.html | 0001140361-26-039380 |
| Document: 0001140361-26-039380.txt | 0001140361-26-039380 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | DEFA14A | $3.69 | awaiting T+20 | — | $3.19 (−13.55%) |
Oct 13, 2026 13d ago | DEF 14A | $3.69 | awaiting T+20 | — | $3.19 (+13.55%) |
Oct 6, 2026 20d ago | Press Release | $3.76 | awaiting T+20 | — | $3.19 (−15.16%) |
Aug 14, 2026 10w ago | Press Release | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.19 (−7.27%) |
Aug 14, 2026 10w ago | 8-K | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.19 (−7.27%) |
Aug 4, 2026 11w ago | 8-K | $2.99 $4.17 | ▲ +39.46% | ▲ +40.70% | $3.19 (+6.69%) |
Jun 30, 2026 16w ago | Insider Cluster | $4.33 $3.49 | ▼ −19.40% | ▼ −17.21% | $3.19 (−26.33%) |
May 15, 2026 23w ago | Press Release | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.19 (+47.00%) |
May 15, 2026 23w ago | 8-K | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.19 (+47.00%) |
Apr 13, 2026 28w ago | EFFECT | $2.35 $2.21 | ▼ −5.96% | ▼ −13.69% | $3.19 (+35.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers